PPIPT00017

Target Protein Information
Protein_Name Erythropoietin receptor
Protein_Sequence MDKLRVPLWPRVGPLCLLLAGAAWAPSPSLPDPKFESKAALLASRGSEELLCFTQRLEDLVCFWEEAASSGMDFNYSFSYQLEGESRKSCSLHQAPTVRGSVRFWCSLPTADTSSFVPLELQVTEASGSPRYHRIIHINEVVLLDAPAGLLARRAEEGSHVVLRWLPPPGAPMTTHIRYEVDVSAGNRAGGTQRVEVLEGRTECVLSNLRGGTRYTFAVRARMAEPSFSGFWSAWSEPASLLTASDLDPLILTLSLILVLISLLLTVLALLSHRRTLQQKIWPGIPSPESEFEGLFTTHKGNFQLWLLQRDGCLWWSPGSSFPEDPPAHLEVLSEPRWAVTQAGDPGADDEGPLLEPVGSEHAQDTYLVLDKWLLPRTPCSENLSGPGGSVDPVTMDEASETSSCPSDLASKPRPEGTSPSSFEYTILDPSSQLLCPRALPPELPPTPPHLKYLYLVVSDSGISTDYSSGGSQGVHGDSSDGPYSHPYENSLVPDSEPLHPGYVACS
Organism_Source Mus musculus
Functional_Classification Class I cytokine receptor
Cellular_Localization Plasma membrane
Gene_Names Epor
UniProt_ID P14753
Protein-Protein Interaction Networks
Peptide Basic Information
Peptide_Name ML5-1
Peptide_Sequence AGLRSRAHLRRALA
Peptide_Length 14
Peptide_SMILES CC(C)C[C@H](NC(=O)CNC(=O)[C@H](C)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O
Chemical_Modification None
Cyclization_Method None
Linear/Cyclic Cyclic
N-terminal_Modification Free
C-terminal_Modification Free
Amino_Acid_Distribution
Peptide Physicochemical
Molecular_Weight 1547.83
Aliphatic_Index 112.14286
Aromaticity 0.00000
Average_Rotatable_Bonds 3.71429
Charge_at_pH_7 4.08888
Isoelectric_point 12.97715
Number_of_Hydrogen_Bond_Acceptors 21
Number_of_Hydrogen_Bond_Donors 29
Topological_Polar_Surface_Area 738.13000
X_logP_energy -8.43882
Interaction Information
Affinity KD=78.28 uM
Affinity_Assay Surface Plasmon Resonance
PDB_ID None
Type Agonist
Structure
Reference Information
Document_Type Patent
Title USE OF ERYTHROPOIETIN - DERIVED PEPTIDE THROUGH EFFECT ON CELL DAMAGE PREVENTION THEREOF
Release_Year 2020
Patent_ID US20200407410A1